title: Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico.
abstract: Breast cancer is the most common female malignancy in Puerto Rico. Cases with human epidermal growth factor receptor 2 (HER-2) oncoprotein overamplification are associated with aggressive clinical behavior. Given the limited availability of information for Puerto Rico, we aimed to evaluate the prevalence and clinical correlates of HER-2 gene overexpression among a hospital-based female population of breast cancer cases. We analyzed data from 1,049 female patients with invasive breast cancer (diagnosed 2000-2005) at the I. González Martínez Oncologic Hospital and the Auxilio Mutuo Hospital. HER-2 status and other clinical characteristics were retrieved from the hospitals' cancer registries, from the Puerto Rico Central Cancer Registry, and from a review of medical and pathological records. Prevalence odds ratios were estimated with 95% confidence intervals, using logistic regression models to quantify the association between HER-2 status and different clinicophatological factors. The overall prevalence of positive HER-2 expression was 22.5%. In the multivariate logistic regression model, factors significantly associated with HER-2 positivity included a diagnosis age of < 50 years, having a tumor with negative progesterone receptor (PR) status, and having regional disease (p < 0.05). No significant differences in HER-2 positivity were observed by tumor histology or estrogen receptor (ER) status (p > 0.05). This is the most comprehensive epidemiological study to date on HER-2 status in Puerto Rico. The prevalence and correlates of HER-2 overexpression in this study are comparable to those observed in US populations. Study results will aid in the development of breast cancer control strategies in Puerto Rico.
authors.affiliation: Cancer Control and Population Sciences Program, University of Puerto Rico Comprehensive Cancer Center, San Juan. ana.ortiz7@upr.edu
authors.forename: Ana P
authors.initials: AP
authors.lastname: Ortiz
authors.forename: Orquídea
authors.initials: O
authors.lastname: Frías
authors.forename: Carmen
authors.initials: C
authors.lastname: González-Keelan
authors.forename: Erick
authors.initials: E
authors.lastname: Suárez
authors.forename: David
authors.initials: D
authors.lastname: Capó
authors.forename: Javier
authors.initials: J
authors.lastname: Pérez
authors.forename: Fernando
authors.initials: F
authors.lastname: Cabanillas
authors.forename: Edna
authors.initials: E
authors.lastname: Mora
mesh_terms: D001943:Breast Neoplasms / Q000737:chemistry* / Q000175:diagnosis*; D005260:Female; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D011647:Puerto Rico; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D012189:Retrospective Studies
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases
references.citation: P R Health Sci J. 2002 Dec;21(4):299-303
references.pmid: 12572236
references.citation: Breast Cancer Res. 2009;11(3):R37
references.pmid: 19538720
references.citation: Cancer Metastasis Rev. 2003 Mar;22(1):47-53
references.pmid: 12716036
references.citation: Jpn J Cancer Res. 1992 Aug;83(8):859-65
references.pmid: 1356959
references.citation: Br J Cancer. 2009 Mar 10;100(5):680-3
references.pmid: 19223897
references.citation: Science. 1989 May 12;244(4905):707-12
references.pmid: 2470152
references.citation: Int J Oncol. 1999 Jun;14(6):1021-37
references.pmid: 10339653
references.citation: Arch Surg. 2000 Dec;135(12):1469-74
references.pmid: 11115354
references.citation: J Clin Oncol. 2007 Jan 1;25(1):118-45
references.pmid: 17159189
references.citation: Breast J. 2010 Nov-Dec;16(6):666-8
references.pmid: 21070450
references.citation: J Clin Pathol. 2005 Jun;58(6):611-6
references.pmid: 15917412
references.citation: Int J Cancer. 2007 Aug 15;121(4):911-4
references.pmid: 17455245
references.citation: Breast J. 2009 Nov-Dec;15(6):593-602
references.pmid: 19764994
references.citation: Hum Pathol. 1992 Sep;23(9):974-9
references.pmid: 1355464
references.citation: Mol Cell Biol. 1987 May;7(5):2019-23
references.pmid: 3299059
references.citation: Pathology. 2006 Dec;38(6):528-33
references.pmid: 17393979
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: Clin Cancer Res. 2002 Feb;8(2):520-5
references.pmid: 11839672
references.citation: P R Health Sci J. 2000 Mar;19(1):7-13
references.pmid: 10761199
references.citation: J Natl Cancer Inst. 1994 May 4;86(9):705-12
references.pmid: 7908990
references.citation: Cancer Res. 1989 Dec 1;49(23):6675-9
references.pmid: 2573420
references.citation: J Clin Oncol. 2001 Mar 15;19(6):1865-78
references.pmid: 11251019
references.citation: Cancer. 2005 Nov 15;104(10):2189-96
references.pmid: 16208704
references.citation: Eur J Cancer. 2007 Feb;43(3):497-509
references.pmid: 17223541
references.citation: Cell Mol Biol (Noisy-le-grand). 2001 Sep;47(6):1025-32
references.pmid: 11785652
references.citation: Cancer. 2004 Sep 15;101(6):1293-301
references.pmid: 15368321
references.citation: J Clin Oncol. 2007 Oct 1;25(28):4423-30
references.pmid: 17906205
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):41-7
references.pmid: 15668474
references.citation: Mod Pathol. 2002 Dec;15(12):1318-25
references.pmid: 12481013
references.citation: Cancer Res. 1989 Dec 15;49(24 Pt 1):6941-4
references.pmid: 2573424
references.citation: J Natl Cancer Inst. 2003 Jan 15;95(2):142-53
references.pmid: 12529347
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5700-6
references.pmid: 19884543
references.citation: JAMA. 2003 Oct 8;290(14):1838-42
references.pmid: 14532299
references.citation: Cancer Res. 1991 Feb 1;51(3):944-8
references.pmid: 1988136
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: J Coll Physicians Surg Pak. 2009 May;19(5):297-9
references.pmid: 19409162
references.citation: Cancer Epidemiol. 2009 Aug;33(2):113-7
references.pmid: 19679057